Question Bank › The streak is alive

The streak is alive

The streak is alive: management narrates back-to-back quarters of the same improvement and shows this quarter extended i

Calls Tested
444
Answered YES
38
Hit Rate
8.6%
rare by design

Flex Ltd. (FLEX) — this company's answers

NO on the Q1 2018 call 2017-07-28 F
The model's full reasoning — Q1 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否将刚报告的季度描述为同一业务领域连续改善的最新一步,并明确与前一时期或连续时期联系起来,且当前时期有实际证据表明该序列再次延伸。 检查记录内容: - 管理层提到HRS业务连续第30个季度同比增长("HRS revenue grew for the 30th straight quarter on a year-over-year basis"),并预计下一季度将连续第31个季度增长。这是明确的连续季度增长序列,且是同比比较,但"30th straight quarter"表明连续多个季度增长,且当前季度是其中之一。但注意,这是同比比较,不是环比比较。然而,连续30个季度同比增长本身就是一个连续序列,且管理层明确说"30th straight quarter",这符合"连续时期"的框架。但问题要求"improved again this period on top of improvement in the immediately prior period",即环比改善。这里说的是同比,但连续30个季度同比改善,隐含了每个季度都比去年同期好,但未必比上一季度好。不过,通常这种表述也暗示了持续改善。但更严格地说,问题要求"quarter-to-quarter chaining",即环比。这里没有明确说环比,但"straight quarter"通常指连续季度,且是同比。然而,管理层也提到HRS的增长率在加速("we expect HRS’s growth will step up even further"),但那是预期。当前季度是5.5%增长,下一季度预期10-20%增长,但那是预期,不是当前证据。 另外,IEI业务:管理层说"IEI had another very strong quarter with revenue coming in at $1.4 billion, up 8% year-over-year, above the forecast of flat to up 5%. IEI’s sales hit another – quarterly record revenues level",这里"another"暗示之前也有记录,但未明确连续几个季度。且是同比。 还有,管理层提到"our first quarter results were within our guidance ranges",没有明确说连续改善。 关键点:问题要求"THE LATEST STEP IS REAL AND CURRENT"且"MANAGEMENT TREATS THE SEQUENCE AS STILL RUNNING"。对于HRS,管理层明确说"30th straight quarter",且预期下一季度继续,这符合。但这是同比,不是环比。然而,问题说"improved again this period on top of improvement in the immediately prior period",即环比。但连续30个季度同比改善,实际上每个季度都比去年同期好,但可能环比有波动。不过,通常这种表述被视为连续改善。但更严格地,问题要求"quarter-to-quarter chaining",即环比。管理层没有明确说环比改善,只说同比。但"straight quarter"通常指连续季度,且是同比。然而,在电话会议中,管理层也提到"we expect HRS’s growth will step up even further",但那是预期。 另外,管理层提到"our first quarter results were within our guidance ranges",没有说连续改善。 还有,管理层提到"we are in an investment year",没有说连续改善。 检查是否有其他部分:管理层提到"our strong cash flow generation remains the hallmark of Flex and enables us to make strategic investments",但那是现金流,不是业务改善。 在回答中,管理层提到"we had no 10% or greater customers for the 6th consecutive quarters",但那是客户集中度,不是改善。 所以,唯一明确的是HRS的连续30个季度同比增长,但那是同比,且管理层明确说"30th straight quarter",这可以视为连续序列。但问题要求"improved again this period on top of improvement in the immediately prior period",即环比。然而,连续30个季度同比改善,隐含了每个季度都比去年同期好,但未必比上一季度好。但通常,这种表述被视为持续改善。不过,问题明确说"comparisons made only against the year-ago period"不符合,但这里"straight quarter"是同比,但连续多个季度同比改善,实际上也隐含了环比改善吗?不一定,因为可能某个季度同比改善但环比下降。但管理层没有提供环比数据。 另外,管理层提到"IEI’s sales hit another – quarterly record revenues level","another"暗示之前也有记录,但未明确连续。 还有,管理层提到"our first quarter results were within ou

← Back to the full FLEX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — explicitly connecting this period to the immediately preceding period or periods as one continuing climb — with real, current-period evidence that the sequence extended again? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent pattern with all three of the following present: (1) A NAMED IMPROVEMENT THAT HAS NOW REPEATED ACROSS CONSECUTIVE PERIODS. Management identifies something specific about the business — such as orders, customers, volumes, output, utilization, activity, bookings, profitability, or the performance of a particular product, operation, or market — and describes it as having improved again this period on top of improvement in the immediately prior period or a run of recent consecutive periods. The chaining must be management's own sequential framing — for example, 'another quarter of growth,' 'our fourth consecutive quarter of...', 'improved again from last quarter,' 'each quarter this year has been stronger than the one before,' or equivalent language linking this period to the one(s) just before it. Comparisons made only against the year-ago period, or general claims of momentum without sequential linkage, do not qualify. (2) THE LATEST STEP IS REAL AND CURRENT. The extension of the streak in the just-reported period is grounded in things that actually happened — actual orders, sales, customers, volumes, shipments, activity, or results in this period described as above the prior period's level — not in forecasts, pipeline, or expectations of continued improvement. (3) MANAGEMENT TREATS THE SEQUENCE AS STILL RUNNING, DRIVEN BY SOMETHING OF THE COMPANY'S OWN. Management attributes the repeating improvement mainly to drivers attached to the company itself — its offering, customers, capabilities, capacity, or changes it made — that remain in force now, and conveys, directly or plainly in substance, that the sequence is continuing rather than concluded: the same drivers are still working, further steps are already forming, or the exit pace is at or above the period's level. Answer NO if the improvement is described only against the year-ago quarter or an easy comparison, with no explicit quarter-to-quarter chaining by management. NO if the period is presented as a single strong quarter, a rebound, or an inflection without a preceding consecutive run. NO if the streak is attributed mainly to external conditions — commodity prices, industry-wide shortage, restocking, pull-forward, seasonality, weather, or macro tailwinds — or to one-time events. NO if management itself signals the run is peaking, normalizing, or expected to pause. NO if the sequential improvement is only in cost cutting or shrinking losses on a declining business. NO if the streak framing appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
CRGO Freightos Limited Q1 2024 2024-05-20 C+
WRBY Warby Parker Inc. Q1 2024 2024-05-09 A
MNKD MannKind Corporation Q4 2023 2024-02-27 C
DXCM DexCom, Inc. Q4 2023 2024-02-08 B+
MFC Manulife Financial Corporation Q3 2023 2023-11-09 C+
BMBL Bumble Inc. Q3 2023 2023-11-07 F
GOLD Barrick Gold Corporation Q3 2023 2023-11-02 C
ALL The Allstate Corporation Q3 2023 2023-11-02 C+
GRBK Green Brick Partners, Inc. Q3 2023 2023-11-01 B
TEL TE Connectivity Ltd. Q4 2023 2023-11-01 B
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
AEIS Advanced Energy Industries, Inc. Q2 2023 2023-08-03 B
PFIE Profire Energy, Inc. Q1 2023 2023-05-13 B
SPIR Spire Global, Inc. Q1 2023 2023-05-10 B
TSN Tyson Foods, Inc. Q2 2023 2023-05-08 D
CALX Calix, Inc. Q1 2023 2023-04-20 C+
TGT Target Corporation Q4 2022 2023-02-28 C
VRE Veris Residential, Inc. Q4 2022 2023-02-22 D
TOST Toast, Inc. Q4 2022 2023-02-16 C+
PI Impinj, Inc. Q4 2022 2023-02-08 B+
PKOH Park-Ohio Holdings Corp. Q3 2022 2022-11-13 B
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
KFY Korn Ferry Q4 2022 2022-06-22 B
WRB W. R. Berkley Corporation Q1 2022 2022-04-26 B
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
ALHC Alignment Healthcare, Inc. Q3 2021 2021-11-06 B+
CYBR CyberArk Software Ltd. Q3 2021 2021-11-04 B+
ASAN Asana, Inc. Q2 2022 2021-09-01 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
ALB Albemarle Corporation Q3 2018 2018-11-08 B
FMS Fresenius Medical Care AG & Co. KGaA Q2 2018 2018-07-31 C
ORAN Orange SA Q2 2018 2018-07-26 B
NOVT Novanta Inc. Q4 2017 2018-05-12 B+
EPC Edgewell Personal Care Company Q3 2017 2017-08-08 D
CNS Cohen & Steers, Inc. Q2 2017 2017-07-20 B
FNV Franco-Nevada Corporation Q3 2016 2016-11-08 B+
GES Guess?, Inc. Q1 2017 2016-05-25 F
SAN Banco Santander, S.A. Q4 2015 2016-01-27 B

How the model reasoned

MNKD · Q4 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES The transcript explicitly frames the just-reported quarter as the second consecutive (or second successive) profitable quarter for the endocrine business unit and for the Company overall. Management ties this directly to actual results in the current period (net income of $1 million GAAP and $7 million non-GAAP in Q4) following the prior 2023 quarter, and states they will continue to focus on growing the profitability of the endocrine business unit, which has had a positive contribution for two straight quarters.
CYBR · Q3 2021 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Udi Mokady explicitly frames Q3 as “another amazing quarter” that follows “an incredible second quarter,” using the single word “acceleration” to describe the quarter. He then quantifies the extension with concrete current-period metrics: subscription ARR growth accelerated to 131 % (reaching $139 million), total 38 % ARR growth (reaching $344 million), recurring revenue growth accelerated to 41 % ($89 million), and new logos accelerated to over 230.
MFC · Q3 2023 → YESThe question is: Does management present the just-reported period as THE LATEST STEP IN AN UNBROKEN, STILL-RUNNING SEQUENCE OF QUARTER-AFTER-QUARTER IMPROVEMENT IN THE SAME PART OF THE BUSINESS — expl...YES Roy Gori explicitly frames core ROE as having been ahead of the 15%+ medium-term target for the second consecutive quarter, while noting a 35% rise in core EPS this quarter (on top of steady year-on-year growth in core earnings over the past three quarters). Colin reinforces the sequential nature by stating that core ROE “increase[d] to 16.8%” this quarter.

More from the question bank

Stretched by business that already arrivedMoney already collected for work not yet donActed like it's already biggerRepeat customers are now the ones asking forThe knock on the company is going staleWhere the money wentAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.